Results 241 to 250 of about 39,430 (282)

A cDC1‐NK/T‐Malignant Cell Circuit Drives Immunogenic Remodeling Under PD‐1 Blockade in Gastric Cancer

Cancer Science, EarlyView.
Chemotherapy combined with nivolumab reshapes the gastric cancer tumor microenvironment (TME) and is accompanied by an enrichment of reduced cytotoxicity NK (RC‐NK) cells. Rather than acting as classical cytotoxic effectors, these RC‐NK cells appear to shape the TME by promoting an immunostimulatory circuit that engages adaptive immunity.
Takuya Nakatsuru, Hiroki Yamashita, Chiaki Mashima, Guoqiang Zhang, Hitoshi Saito, Tatsunori Minamide, Keita H. Nagaoka, Ryo Kamata, Shunsuke A. Sakai, Gaku Yamamoto, Tomoko Y. Morita, Kazuki Nakai, Yumi Hakozaki, Kumi Kinoshita, Yui Takahashi, Izuma Nakayama, Akihito Kawazoe, Yuko Ishii, Sai M. Pulukuri, Hiroshi Haeno, Yukie Kashima, Kohei Shitara, Tomonori Yano, Takeshi Saito, Akihiro Ohashi   +24 more
wiley   +1 more source

Complement-Modulating Mechanisms of Ginkgo biloba Extract in Dry AMD: Insights From Molecular Docking and Dynamics Simulations. [PDF]

Transl Vis Sci Technol
Huang T, Jiang D, Wang D, Dong Z, Hou Y, Li X, Deng X, Liu X.   +7 more
europepmc   +1 more source

Differential complement activation by alloantibodies in sickle cell hyperhaemolysis syndrome may influence disease course

British Journal of Haematology, EarlyView.
Mamie M. Thant, Jahnavi Gollamudi, Stefanie W. Benoit, Satheesh Chonat, Jose A. Cancelas   +4 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Crystallization of human complement component C5

Acta Crystallographica Section D Biological Crystallography, 1998
Human complement component C5 has been crystallized using a low-salt batch technique. The crystals are large hexagonal bi-pyramids often larger than 1.5 mm. Although these crystals were grown in low salt (0.1 M NaCl), they are remarkably stable for at least 2 months at 281 K and they are not dissolved in aqueous buffers containing up to 2 M sodium ...
Discipio, R G, Jenner, L, Thirup, S, Sottrup-Jensen, L, Nyborg, J, Stura, E   +5 more
openaire   +3 more sources

Structure/function of C5 convertases of complement

International Immunopharmacology, 2001
C5 convertases are serine proteases that cleave both C3 and C5. Alternative pathway C3/C5 convertases formed with monomeric C3b (C3b,Bb) because of their weak interaction with C5 primarily cleave C3 thereby opsonizing the cell surface with C3b. In contrast, C3/C5 convertases formed with a high density of C3b/cell exhibit higher affinities for C5 as ...
N, Rawal, M K, Pangburn
openaire   +2 more sources

Purification of Human Complement Protein C5

2013
Complement C5 is cleaved by proteolysis in the terminal phase of complement activation generating the pro-inflammatory C5a and membrane attack complex nucleator C5b. Whereas purification of its paralogues C3 and C4 from plasma is relatively straightforward, C5 purification is more complicated due to the lower amounts present and overlaps with the much ...
Sottrup-Jensen, Lars, Andersen, Gregers Rom; id_orcid 0000-0001-6292-3319   +1 more
openaire   +3 more sources

Structure and function of complement C5 convertase enzymes

Biochemical Society Transactions, 2002
The multisubunit enzymes of the complement system that cleave C5 have many unusual properties, the most striking of which is that they acquire their specificity for C5 following cleavage of another substrate C3. C5 convertases are assemblies of two proteins C4b and C2a (classical or lectin pathways) or C3b and Bb (alternative pathway) and additional ...
M K, Pangburn, N, Rawal
openaire   +2 more sources

Genetic defect in secretion of complement C5 in mice

Nature, 1979
A genetic deficiency of the fifth (C5) component of complement1-3, a serum glycoprotein of molecular weight (MW) 220,000 (ref. 4), has been found in 39% of inbred strains of mice3. Sera of deficient mice lack detectable C5 activity and protein2,3. In addition deficient mice produce antibody to mouse C5 when injected with sera from C5 sufficient (normal)
Ooi, Y M, Colten, H R
openaire   +2 more sources

A small-molecule inhibitor of C5 complement protein

Nature Chemical Biology, 2019
The complement pathway is an important part of the immune system, and uncontrolled activation is implicated in many diseases. The human complement component 5 protein (C5) is a validated drug target within the complement pathway, as an anti-C5 antibody (Soliris) is an approved therapy for paroxysmal nocturnal hemoglobinuria.
Keith Jendza, Mitsunori Kato, Michael Salcius, Honnappa Srinivas, Andrea De Erkenez, Anh Nguyen, Doug McLaughlin, Celine Be, Christian Wiesmann, Jason Murphy, Philippe Bolduc, Muneto Mogi, Jose Duca, Abdel Namil, Michael Capparelli, Veronique Darsigny, Erik Meredith, Ritesh Tichkule, Luciana Ferrara, Jessica Heyder, Fang Liu, Patricia A. Horton, Michael J. Romanowski, Markus Schirle, Nello Mainolfi, Karen Anderson, Gregory A. Michaud   +26 more
openaire   +2 more sources

Accelerated Wound Healing with Topical Application of Complement C5

Plastic & Reconstructive Surgery, 2012
Delayed-healing traumatic, surgical, and chronic wounds can be detrimental to patients and the health care system. The authors set out to investigate the effects of complement C5, a naturally occurring chemotactic cytokine, on wounds.The authors examined the effects of complement C5 on the rat paired skin incision model.
Hani, Sinno, Meenakshi, Malhotra, Justyn, Lutfy, Barbara, Jardin, Sebastian, Winocour, Fadi, Brimo, Lorne, Beckman, Kevin, Watters, Anie, Philip, Bruce, Williams, Satya, Prakash   +10 more
openaire   +2 more sources